Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
This study has been completed.
Study NCT01273532   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received on January 7, 2011.   Last Updated on March 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Healthy Volunteer
Interventions listed in this trial
tapentadol (CG5503) ER 100-mg TRF
tapentadol (CG5503) ER 50-mg TRF
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services